|
Phase II study of gedatolisib for small-cell lung cancer (SCLC) patients (pts) with genetic alterations in PI3K/AKT/mTOR pathway based on a large-scale nationwide genomic screening network in Japan (EAGLE-PAT/LC-SCRUM-Japan). |
|
|
Honoraria - Abbvie; Amco; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; MSD; Ono Pharmaceutical; Taiho Pharmaceutical |
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim |
Research Funding - Abbvie; Amgen; Daiichi Sankyo; MSD |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical |
Research Funding - AstraZeneca (Inst); MSD (Inst) |
|
|
Honoraria - Chugai/Roche; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical |
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai/Roche (Inst); Lilly (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Taiho Pharmaceutical |
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Pfizer (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical |
Research Funding - Lilly (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Sysmex |
Consulting or Advisory Role - ASLAN Pharmaceuticals; Boehringer Ingelheim; Eisai; Otsuka; PRA health science; Takeda |
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); IQVIA (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Merck Sharp & Dohme; Ono Pharmaceutical; Pfizer; Roche |
Research Funding - AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst) |
|
|
|
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck KGaA; Merck Sharp & Dohme; Nippon Kayaku; Nitto Denko; Novartis; Ono Pharmaceutical; Pfizer; Roche; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Chugai Pharma; Lilly; Merck Serono; MSD; Nitto Denko; Pfizer |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb; Chugai Pharma (Inst); Kyorin; Kyowa Hakko Kirin; Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis; Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron; Taiho Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Asahi Kasei (I) |
Honoraria - AstraZeneca; Chugai Pharma; Pfizer; Taiho Pharmaceutical |
|
|
Honoraria - AstraZeneca; Chugai Pharma; MSD (Inst); Novartis; Pfizer |
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst) |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Novartis; Pfizer; Shionogi; Taiho Pharmaceutical |
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Pfizer (Inst) |
|
|
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma |
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices; Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Guardant Health; IQvia; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Otsuka |
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; Loxo; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Riken Genesis; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Takeda; Xcoo |